Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22005196 | 0.88 | RECQL (0.33) | RECQLHPGDALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL12568580 | 0.85 | RECQL (0.33) | GAARECQLHPGDALDH1A1HTT | |
| SCHEMBL30440949 | 0.84 | TERT (0.35) | — | |
| SCHEMBL9315493 | 0.84 | — | — | |
| SCHEMBL21075889 | 0.84 | ALDH1A1 (0.34) | GAAMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL10046524 | 0.82 | NPFFR1 (0.39) | GAAMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL10136052 | 0.82 | NPFFR1 (0.39) | GAAMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL8140158 | 0.82 | ALDH1A1 (0.33) | RECQLMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL19643563 | 0.82 | RECQL (0.41) | GAARECQLHPGDALDH1A1HTT | |
| SCHEMBL17369556 | 0.81 | HDAC3 (0.32) | GAAHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200158737-A1 | METHODS OF MEASURING UBIQUITIN-LIKE MODIFICATIONS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200158737-A1 | METHODS OF MEASURING UBIQUITIN-LIKE MODIFICATIONS | UCHL1, UCHL3, UCHL5 | GAA 1654/4885RECQL 3288/4885MEN1 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.